Pretreatment Resistance to Integrase Inhibitors in the Swiss HIV Cohort Study From 1995 to 2025
Tom Loosli, Marco Labarile, Nanina Anderegg, Paul Frischknecht et autres
0 citationsOpen Forum Infectious Diseases
Tom Loosli
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
25Publications signalées
272Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV Research and TreatmentHIV-related health complications and treatmentsBiochemical and Molecular Research
Publications récentes
Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined Scenarios
RW Shafer, Kaiming Tao, Tom Loosli, Ana Abecasis et autres
0 citationsViruses
Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined Scenarios
Robert W. Shafer, Kaiming Tao, Tom Loosli, Ana Abecasis et autres
0 citationsZurich Open Repository and Archive (University of Zurich)
Global and regional molecular epidemiology of HIV-1 during 1990–2024: systematic review, global survey, and analysis of prevalence
Ayisha Khalid, Lucy Gettins, Lauren Scullion, Xin Liu et autres
2 citationsThe Lancet Infectious Diseases
Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study
Nuri Han, Tom Loosli, Mamatha Sauermann, İpek Çelikağ et autres
0 citationsJournal of Antimicrobial Chemotherapy
Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study.
Nuri Han, Tom Loosli, Mamatha Sauermann, İpek Çelikağ et autres
0 citationsOpen Access CRIS of the University of Bern
Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study
Nuri Han, Tom Loosli, Mamatha Sauermann, İpek Çelikağ et autres
0 citationsZurich Open Repository and Archive (University of Zurich)
The effect of long-acting cabotegravir and rilpivirine treatment on drug resistance in South Africa: a modelling study
Nuri Han, Tom Loosli, Nanina Anderegg, Anthony Hauser et autres
3 citationsThe Lancet Global Health
Novel integrase mutations linked to genotypic DTG resistance in non-B HIV-1 strains from African participants: The DTG RESIST study
Nuri Han, Tom Loosli, Mamatha Sauermann, İpek Çelikağ et autres
1 citationmedRxiv
Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence
Cameron T. Nutt, Richard Lessells, Winnie Muyindike, Lyra S. Johnson et autres
2 citationsClinical Infectious Diseases
a modelling study
Andrew Phillips, Loveleen Bansi-Matharu, JJ van Oosterhout, Emily Hyle et autres
0 citationsPortuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Evaluation of antiretroviral regimen switching options in adults with HIV with sustained viral load non-suppression on dolutegravir, lamivudine, and tenofovir in eastern, central, southern, and western Africa: a modelling study
Andrew Phillips, Loveleen Bansi‐Matharu, Joep J. van Oosterhout, Emily P. Hyle et autres
7 citationsThe Lancet HIV
BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.